AP NEWS

Sensory Neuropathy - Pipeline Insight, 2019 by Developmental Stage, Associated Indications, Route of Administration, and Molecule Type - ResearchAndMarkets.com

January 31, 2019

DUBLIN--(BUSINESS WIRE)--Jan 31, 2019--The “Sensory Neuropathy - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Sensory Neuropathy - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across Sensory Neuropathy development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope

The report provides a snapshot of the pipeline development for the Sensory Neuropathy The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Sensory Neuropathy The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Sensory Neuropathy The report also covers the dormant and discontinued pipeline projects related to Sensory Neuropathy

Topics Covered

1. Report Introduction

2. Sensory Neuropathy Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Sensory Neuropathy

4. Comparative Analysis

5. Products in Clinical Stage

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

Product Description Research and Development Product Development Activities

Companies Featured

Araim Pharmaceuticals CSL Limited GeNeuro SA Mitsubishi Tanabe Pharma Corporation Neuren Pharmaceuticals Limited Pfizer Inc. Pharnext SAS Polyneuron Pharmaceuticals AG RegeneRx Biopharmaceuticals Sanofi Shire PLC Teijin Pharma Limited

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rhr9qw/sensory?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190131005743/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/31/2019 12:30 PM/DISC: 01/31/2019 12:30 PM

http://www.businesswire.com/news/home/20190131005743/en

AP RADIO
Update hourly